Online inquiry

IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9807MR)

This product GTTS-WQ9807MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets BTLA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001085357.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 151888
UniProt ID Q7Z6A9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9807MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2956MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ9513MR IVTScrip™ mRNA-Anti-EGFR, J2898A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA J2898A
GTTS-WQ7263MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ13066MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, PEG-IFN-SA(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PEG-IFN-SA
GTTS-WQ4285MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB-054
GTTS-WQ8725MR IVTScrip™ mRNA-Anti-CCR5, HuPRO-140(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA HuPRO-140
GTTS-WQ5831MR IVTScrip™ mRNA-Anti-CD3E, ChAglyCD(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ChAglyCD
GTTS-WQ6208MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW